TY - JOUR
T1 - Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands
T2 - About one in a million
AU - Daniëlle van Pelt, E
AU - Wong, Yu Yi M
AU - Ketelslegers, Immy A
AU - Siepman, Dorine Am
AU - Hamann, Dörte
AU - Hintzen, Rogier Q
PY - 2016/1/26
Y1 - 2016/1/26
N2 - Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves and spinal cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-IgG) are detected. Here we assessed a nationwide incidence of AQP4-IgG-seropositive NMO spectrum disorders (NMOSD) in the Netherlands based on results of one central laboratory. Data were collected since the introduction of the highly sensitive cell-based assay for six consecutive years. Samples from 2795 individual patients have been received; of them 94 (3.4%) were seropositive. Based on the Dutch population with 16.6 million inhabitants, the mean incidence of AQP4-IgG-seropositive NMOSD was calculated at 0.09 per 100,000 people.
AB - Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves and spinal cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-IgG) are detected. Here we assessed a nationwide incidence of AQP4-IgG-seropositive NMO spectrum disorders (NMOSD) in the Netherlands based on results of one central laboratory. Data were collected since the introduction of the highly sensitive cell-based assay for six consecutive years. Samples from 2795 individual patients have been received; of them 94 (3.4%) were seropositive. Based on the Dutch population with 16.6 million inhabitants, the mean incidence of AQP4-IgG-seropositive NMOSD was calculated at 0.09 per 100,000 people.
U2 - 10.1177/2055217315625652
DO - 10.1177/2055217315625652
M3 - Article
C2 - 28607712
SN - 2055-2173
VL - 2
SP - 2055217315625652
JO - Multiple sclerosis journal - experimental, translational and clinical
JF - Multiple sclerosis journal - experimental, translational and clinical
ER -